Why the study?
Apixaban could be an option for thromboembolism prevention in children with congenital or acquired heart disease, requiring characterization of pharmacokinetics, pharmacodynamics, and appropriate dosing regimens.
Does a weight-tiered dosing regimen of apixaban achieve target adult exposures in pediatric patients aged 28 days to < 18 years with congenital or acquired heart disease?
Does a weight-tiered dosing regimen of apixaban achieve target adult exposures in pediatric patients aged 28 days to < 18 years with congenital or acquired heart disease?
A weight-tiered dosing regimen of apixaban in pediatric patients with congenital or acquired heart disease achieves target exposures comparable to adult populations, supporting its use for thromboembolism prevention.
Supports proposed apixaban dosing in pediatric CAHD; extends prior PPK models but leaves phase 3 confirmation open.
Apixaban is an oral direct inhibitor of factor Xa (FXa) that could be a treatment option for thromboembolism prevention in children with congenital or acquired heart disease (CAHD). Data from SAXOPHONE, a phase II pediatric study, were used to update a previously developed population pharmacokinetics (PPK) model and to assess the covariate effect of patient type on PK parameters while retaining previous covariates. Stochastic simulations were performed to assess whether the proposed dosing regimens in pediatric patients aged 28 days to < 18 years matched adult exposures. The relationship between anti-Factor Xa (AXA) and apixaban concentration, as well as apixaban concentration and chromogenic FX, were evaluated. Apixaban dose adjustment in response to the growth of pediatric patients and changes in age and weight were also assessed. Apixaban PK in pediatric patients with CAHD was well characterized by a 2-compartment model with first-order absorption, dose-dependent F1, and first-order elimination. Apixaban apparent clearance (CL/F) and apparent volume of distribution in the central compartment (Vc/F) increased with increasing body weight. Apixaban CL/F was lower in pediatric patients with CAHD compared to adults and other pediatric patients. The fixed dose by weight-tiered dosing regimen for pediatric patients with CAHD (28 days to < 18 years) achieved target exposures similar to adult VTE treatment and nonvalvular atrial fibrillation populations. A linear PK/PD relationship between apixaban and AXA was observed. Inhibition of FXa was observed across weight tiers. Apixaban dose adjustment in response to weight gain resulted in exposures similar to target adult exposures.
No takes yet. Share an insight, caveat, or question.
Ajavon‐Hartmann et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: